AD)	

Award Number: DAMD17-00-1-0238

TITLE: Development of Dual Acting Inhibitors for Breast Cancer

PRINCIPAL INVESTIGATOR: Pui Kai Li, Ph.D.

CONTRACTING ORGANIZATION: Ohio State University

Columbus, OH 43210-1239

REPORT DATE: August 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching satisfing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of

Management and Budget, Paperwork Reduction Proj					
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE		3. REPORT TYPE AND DATES COVERED Annual (3 Jul 2002 - 2 Jul 2003)		
	August 2003	Annual (3 Jul	2002 - 2 Ј	ul 2003)	
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS		
Development of Dual Acting Inhibitors for Breast Cancer			DAMD17-00-1-0238		
				•	
	•				
C AUTUONO			4		
6. AUTHOR(S)					
Pui Kai Li, Ph.D.					
7. PERFORMING ORGANIZATION NAI	ME(S) AND ADDRESS(ES)		8 DEDECIDANA	IC OPCANIZATION	
Ohio State University	, , , , , , , , , , , , , , , , , ,		8. PERFORMING ORGANIZATION REPORT NUMBER		
Columbus, OH 43210-1239				,	
•			}		
E-Mail: li.27@osu.edu					
9. SPONSORING / MONITORING			10 SPONSOR	ING / MONITORING	
AGENCY NAME(S) AND ADDRESS(ES)			AGENCY REPORT NUMBER		
U.S. Army Medical Resear	cch and Materiel Comm	and			
Fort Detrick, Maryland					
•					
11. SUPPLEMENTARY NOTES					
·		•			
12a. DISTRIBUTION / AVAILABILITY				12b. DISTRIBUTION CODE	
Approved for Public Rele	ease; Distribution Un	limited			
13. ABSTRACT (Maximum 200 Word	s)				
	•		•		
Purpose: To design dual acting	inhibitors that can block the ena	zyme estrone sulfatase a	ind act as antiest	rogens.	
Scope: The design and synthesis of	30 dual inhibitors are proposed	. The inhibitors contain	4 different struc	ctural core. The synthesized	
inhibitors will be tested on their abil	ity to inhibit the enzyme estron	ne sulfatase and also the	ir abilities to inh	libit the growth of breast	
cancer cells stimulated by estrone su	ılfate. İn addition, selected inhi	bitors will be tested in v	ivo using NMU	-induced mammary tumors	

in rats.

Major findings: More than 83 % (25 out of 30) of the proposed inhibitors have been synthesized. The inhibitors have been tested for their ability to inhibit estrone sulfatase activity of rat liver microsomes at 20 µM concentrations and in the presence of 20 µM of substrate estrone sulfate. All the inhibitors tested so far are more potent than our lead compound Tamoxifen sulfamate. Raloxifene sulfamate (inhibitor 30) is still the most potent compound among the 25 inhibitors we have synthesized. It inhibits more than 95% of the sulfatase activity at 20 µM concentration. It is by far the most potent dual inhibitor we have ever obtained. We have selected inhibitor 30 as one of the compounds for in vivo study using NMU-induced mammary tumors in rats. We have synthesized 4 grams of the compound needed for the study.

14. SUBJECT TERMS			15. NUMBER OF PAGES
			16
Breast Cancer	10		
220000 000000		·	16. PRICE CODE
	18. SECURITY CLASSIFICATION	19. SECURITY CLASSIFICATION	20. LIMITATION OF ABSTRACT
OF REPORT	OF THIS PAGE	OF ABSTRACT	
Unclassified	Unclassified	Unclassified	Unlimited
17. SECURITY CLASSIFICATION OF REPORT			

Table of Contents

Gover1	
SF 2982	
Table of Contents3	
Introduction4	
Body5	
Key Research Accomplishments8	
Reportable Outcomes9	
Conclusions10	
Referencesnor	ıe
Appendices11	

Introduction

Breast cancer is the most common malignancy in the United States. It is estimated that approximately 30 - 40 % of all breast cancers are estrogen-dependent. Currently, the most common treatments use either antiestrogen or aromatase inhibitors. They are effective in 35-40 % of advanced postmenopausal breast cancer patients. In estrogendependent breast cancer patients, the estrogen levels in breast cancer cells are 5-10 times higher than in plasma. One of the possibilities to explain this observation is in situ production of estrogens from precursor substrates in the breast cancer cells. One of the pathways for the in situ production of estrogen is the conversion of androgens to estrogens by the enzyme aromatase (aromatase pathway). Another pathway for the in situ formation of estrogen is through the conversion of estrone sulfate to estrone by the enzyme estrone sulfatase (estrone sulfatase pathway). It has been pointed out that the estrone sulfatase pathway is significant and produce 10 times more estrogen than through the aromatase pathway in breast cancer cells. In addition, estrone sulfatase is also responsible for the conversion of dehydroepiandrosterone sulfate to androst-5-ene-3β,17β-diol, another estrogenic steroid in the body. Thus, potent estrone sulfatase inhibitors are potential agents for the treatment of estrogen-dependent breast cancer. Preliminary studies demonstrated that estrone sulfatase inhibitor can block the growth of NMU-induced tumor in rat stimulated by estrone sulfate. Thus the current approach is to design dual acting inhibitors that can not only block the estrone sulfatase pathway, but also act as antiestrogens. The proposed dual acting inhibitors will have advantage over the current drug treatments. The inhibitors will not only block the formation of estrogen, but also block the stimulatory effect of estrogen on cancer cells. This proposal will design and synthesize of dual acting inhibitors with sulfatase inhibitory and anti-estrogenic activity. The synthesized inhibitors will be tested using enzyme inhibition and cell culture assays. Finally, In vivo studies of dual acting inhibitors using NMU-induced mammary tumor in rats will be performed.

Body

As stated in the introduction, this proposal deals with the design, synthesis and biological testings of dual inhibitors with sulfatase inhibitory and anti-estrogenic activities. A total of 30 inhibitors are proposed. In the first year we have synthesized 16 inhibitors (inhibitors 1-15 and 30 stated in the proposal). In the second year, we completed the synthesis of inhibitors 16-24 proposed in the grant. The remaining compounds (inhibitors 25-29, structures shown below) are completed this year.

$$H_2NO_2SO$$
Inhibitor 25

 H_2NO_2SO
Inhibitor 26

 H_2NO_2SO
Inhibitor 27

 H_2NO_2SO
Inhibitor 28

Inhibitor 29

The syntheses of inhibitors **25-29** carried out according to the literature except the sulfamoylation step. We did not come across any difficulty.

Enzyme Inhibition studies of inhibitors

Inhibitors 25 - 29 were tested for their abilities to inhibit estrone sulfatase activity of rat liver microsomes at 20 μ M concentrations and in the presence of 20 μ M substrate estrone sulfate. At 20 μ M inhibitor concentration, the % inhibiton of sulfatase activity activity range from 9 – 42 %. Raloxifene sulfamate (inhibitor 30) is still the most potent inhibitor among all the inhibitors we synthesized (over 95% inhibition) at the same inhibitor concentration.

When compared all the inhibitors we synthesized, we choose Tamoxifen sulfamate, compound 7 and compound 30 and determine their IC_{50} values on sulfatase inhibition (shown below).

IC₅₀ of steroid sulfatase

$$(CH_3)_2NCH_2CH_2O$$

$$C=C$$

$$C_2H_5$$

$$H_2NO_2SO$$

$$35.9 \mu M$$

(E)-Hydroxytamoxifen sulfamate

$$N(CH_3)_2$$
 OH H_2NO_2SO 4.4 μM

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

Inhibitor 30

Inhibitor 7

We have reported the first inhibitor (E-hydroxytamoxifen sulfamate) with dual activity, inhibiting both estrone sulfatase and also act as antiestrogen. However, E-hydroxytamoxifen sulfamate has weak sulfatase inhibitory activity. In addition, the active estrogen, Z-4-hydroxytamoxifen can be isomerized to the inactive E-hydroxytamoxifen. One alternative to prevent the isomerization is incorporating the ethyl group in the hydroxytamoxifen into a ring such as nafoxidine and diphenylbenzocycloheptene. When compared the sulfatase inhibitory activity of E-Hydroxytamoxifen with one of the analogs of nafoxidine sulfamate (compound 7), the sulfatase inhibitory activity of compound 7 is approximately 8 fold more potent. Most amazingly, replacing the dihydronaphthalene nucleus in compound 7 with a benzothiophene nucleus to form compound 30, the sulfatase inhibitory activity of compound 30 increases another 73 fold and has an IC₅₀ value of 60 nM. Compound 30 is the most potent sulfatase inhibitor among all 30 compounds.

We have requested for a one year no cost extension to complete the in vivo antitumor study of compound 30 on NMU induced mammary tumor in rat.

Key Research Accomplishment

All the proposed inhibitors (compounds 1-30) have been synthesized. All the inhibitors tested so far are more potent than our lead compound E-hydroxytamoxifen sulfamate. Raloxifene sulfamate (inhibitor 30) exhibits an extremely potent sulfatase inhibitory activity. It inhibits more than 95% of the sulfatase activity at 20 μ M concentration and exhibit an IC₅₀ value of 60 nM. It is by far the most potent dual inhibitor we have ever obtained and also the most potent dual inhibitor ever reported in the literature. We have synthesized 4 grams of inhibitor 30 for in vivo antitumor study.

Reportable Outcomes

- 1. A manuscript has been prepared on the synthesis and sulfatase inhibitory activities of dual inhibitors with nafoxidine nucleus (please refer to the appendix).
- 2. Presentation of poster "DESIGN AND SYNTHESES OF DUAL ACTING INHIBITORS FOR BREAST CANCER" at the Era of Hope, Department of Defense Breast Cancer Research Program Meeting, September, 25-28, 2002, Orlando Florida. (abstract attached)
- 3. Oral presentation at the Gordon Conference "Hormonal Carcinogenesis" July 6-11, 2003, Meriden, NH. Seminar title "Estrogen sulfatase and inhibitors in breast cancer".

Personnel receiving pay from the project

Pui-Kai Li

Kyle Selcer

JianDong Shi

Zili Xiao

Jennifer Sarap

Conclusions:

All 30 proposed inhibitors have been synthesized and tested for their ability to inhibit estrone sulfatase activity of rat liver microsomes at 20 μ M concentrations and in the presence of 20 μ M substrate estrone sulfate. The inhibitors belong to the nafoxidine, benzocyclohepterne and raloxifene structural classes. All the inhibitors showed significant inhibition of estrone sulfatase and are more potent than our lead compound Tamoxifen sulfamate. Raloxifene sulfamate (inhibitor 30) exhibits an extremely potent sulfatase inhibitory activity and has been chosen to be one of the compounds for in vivo anti-tumor study. We have synthesized 4 grams of the compound.

APPENDIX COVER SHEET

DESIGN AND SYNTHESES OF DUAL ACTING INHIBITORS FOR BREAST CANCER

Pui-Kai Li, Jiandong Shi, Guo-Hua Chu, Rucha Sane, Jennifer Sarap, Heidi Kabler, Kyle W. Selcer

Division of Med. Chem and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus OH 43210, Department of Medicinal Chemistry, Mylan School of Pharmacy and Department of Biology, School of Natl. & Environ. Sci., Duquesne University, Pittsburgh PA 15282.

E-mail li.27@osu.edu

ABSTRACT: Estrogen levels in breast tumors of post-menopausal women are at least ten times higher than estrogen levels in plasma. The high levels of estrogen in these tumors are presumably due to in situ formation of estrogen, possibly through conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Therefore, inhibitors of estrone sulfatase are potential agents for the treatment of estrogen-dependent breast cancers. Among all the estrone sulfatase inhibitors, estrone-3-O-sulfamate (EMATE) and its analogs are the most potent. EMATE is classified as an active-site directed irreversible inhibitor. Recently, non-steroidal estrone sulfatase inhibitors were developed based on the fact that EMATE was found to be estrogenic. Non-steroidal sulfatase inhibitors such as coumarin sulfamate and (p-O-sulfamoyl)-N-tetradecanoyl tyramine were reported to inactivate estrone sulfatase in an active-site directed manner. It can be concluded that the common functionality for sulfatase inactivation is a phenylsulfamoyl group.

We synthesized (E)-4-hydroxytamoxifen sulfamate as dual inhibitor (inhibitor with sulfatase inhibitor activity and antiestrogenic activity). (E)-Hydroxytamoxifen sulfamate competitively inhibited estrone sulfatase and exhibited apparent Ki of 35.9 ± 4.4 micromolar. It has higher affinity than the substrate estrone sulfate since the Km of the substrate is 90.2 ± 8.0 micromolar. Eight sulfamate analogs with nafoxidine nucleus were synthesized. In addition, four sulfamate analogs with raloxifene nucleus were also synthesized as dual acting agents.

The dual inhibitors were tested for their abilities to inhibit estrone sulfatase activity of rat liver microsomes. The most potent nafoxidine sulfamate and raloxifene sulfamate are 10 (Ki = 4 micromolar) and 60 times (Ki = 60 nanomolar) respectively more potent than (E)-4-hydroxytamoxifen sulfamate in estrone sulfatase inhibition. The dual inhibitors also inhibit the proliferation of estrogen-dependent breast cancer cell growth stimulated by estrone sulfate.

In conclusion, the newly synthesized inhibitors represent potential agents for the treatment of estrogen-dependent breast cancer.

Supported by the U.S. Army Medical Research and Materiel Command under DAMD17-00-1-0238.

SYNTHESIS AND SULFATASE INHIBITORY ACTIVITIES OF CONFORMATIONAL RESTRICTED ANALOGS OF (E) -4-HYDROXYTAMOXIFEN SULFAMATE

Guo-Hua Chu, Jian Dong Shi, Zhigen Hu, Heidi Kabler, Kyle W. Selcer and Pui-Kai Li

[†]Department of Medicinal Chemistry and Pharmaceutics, Mylan School of Pharmacy, Duquesne University, Pittsburgh PA 15282 and Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus OH 43210

Abstract: Eight conformational restricted analogs of (E)-4-hydroxytamoxifen sulfamate are synthesized as estrone sulfatase inhibitors. All the inhibitors significantly inhibited estrone sulfatase activity. Varying the nature of the substituents in R₃ (H, CH₃, OCH₃, OH) has little effect on the sulfatase inhibitory activity. However, inhibitors with pyrrolidinyl group consistently exhibit higher sulfatase inhibitory activities than the inhibitors with dimethylamino groups.

There is substantial evidence that breast tumors in post-menopausal women accumulate high concentration of estrogens^{1,2} and possibly through conversion of estrone sulfate to estrone by the enzyme estrone sulfatase.^{3,4} Several estrone sulfatase inhibitors (both steroidal and non-steroidal) have been developed as potential agents for the treatment of estrogen-dependent breast cancers.^{5,26} Since the pharmacophore for sulfatase inactivation is a phenylsulfamoyl group, it occurs to us that a potent antiestrogen such as (Z) 4-hydroxytamoxifen can be easily converted to the respective sulfamate analog and becomes potential dual inhibitor (inhibitor with sulfatase inhibitor activity and antiestrogenic activity). Recently, we have synthesized (E) 4-hydroxytamoxifen sulfamate (Fig. 1), the sulfamoylated analog of the potent antiestrogen (Z) 4-hydroxytamoxifen, and demonstrated that it is four fold better than the substrate estrone sulfate in binding to estrone sulfatase.²⁷ However, the potent antiestrogen (Z)-4-hydroxytamoxifen has been shown in vitro to isomerize into a mixture of Z and E isomer.²⁸ (E)-4-Hydroxytamoxifen is estrogenic [101, 102].^{29,30} Since the conjugation of the hydroxy group in (Z)-4-hydroxytamoxifen with the central double bond is responsible for the facile isomerization [103].³⁰, one method to fix the configuration of the double bond is incorporating it into a ring such as in nafoxidine. Thus, inhibitors 1 - 8 were synthesized as conformational restricted analogs of (E) 4-hydroxytamoxifen sulfamate.

(E)-4-Hydroxytamoxifen sulfamate

$$\begin{array}{c} \mathsf{Br} & \longrightarrow \mathsf{OH} & \longrightarrow \mathsf{Br} & \longrightarrow \mathsf{OCH_2CO_2Et} & \longrightarrow \mathsf{Br} & \longrightarrow \mathsf{OCH_2CH_2OHBS} \\ \mathsf{g} & & \mathsf{II} & & \mathsf{II} & & \mathsf{II} \\ \mathsf{HO} & & \mathsf{III} & & & \mathsf{II} \\ \mathsf{HO} & & \mathsf{III} & & & \mathsf{II} \\ \mathsf{HO} & & \mathsf{III} & & & \mathsf{III} \\ \mathsf{HO} & & & \mathsf{III} & & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & & & & & \mathsf{III} \\ \mathsf{III} & & & \mathsf{III} \\ \mathsf{III} & & & \mathsf{III} \\ \mathsf{III} & \mathsf{III} \\ \mathsf{III} & & \mathsf{III} \\ \mathsf{III} & \mathsf{IIII} \\ \mathsf{IIII}$$

1, $R_1=R_2=CH_3$, $R_3=H$ 3, $R_1=R_2=CH_3$, $R_3=OCH_3$ 2, $R_1=R_2=R_3=CH_3$, 32, $R_1=R_2=CH_3$, $R_3=OCH_2Ph$ 24, $R_1=R_2=CH_3$, $R_3=H$ 26, $R_1=R_2=CH_3$, $R_3=OCH_3$ $20, R_3 = H$ 22, $R_3 = OCH_3$ 25, $R_1 = R_2 = R_3 = CH_3$, 27, $R_1 = R_2 = CH_3$, $R_3 = OCH_2$ Ph $21, R_3 = CH_3$ $23, R_3 = OCH_2Ph$


5, R_1 , R_2 =-(CH_2)₄, R_3 = H 7, R_1 , R_2 =-(CH_2)₄, R_3 = OCH_3

28, R_1 , R_2 =-(CH₂)₄, R_3 = H 30, R_1 , R_2 =-(CH₂)₄, R_3 = OCH₃ $6, R_1, R_2 = -(CH_2)_4, R_3 = CH_3 + 33, R_1, R_2 = -(CH_2)_4, R_3 = OCH_2Ph + 29, R_1, R_2 = -(CH_2)_4, R_3 = CH_3 + 31, R_1, R_2 = -(CH_2)_4, R_3 = OCH_2Ph + (CH_2)_4, R$

$$R_1$$
 R_2
 N
 OCH_2Ph
 R_1
 R_2
 OCH_2Ph
 R_2
 OCH_2P

Reagents and Conditions: a. BrCH₂CO₂Et, K₂CO₃, acetone, reflux 2.5 h, 99.3 %; b. LiAlH₄, THF, r.t, 2 h; c. TBSCl, Imidazole, DMF, r.t, overnight, 96.4 % for 2 steps; d. Dihydropyran, PPTs, CH₂Cl₂, r.t, 2.5 h, 98 %; e. i) n-BuLi, THF, -78°C, 45 min; ii) 13, -78°C to r.t, 3 h; iii) SiO₂, CH₂Cl₂, r.t, overnight, 65.7% based on 13; f. i) C₅H₅N.HBr₃, CH₂Cl₂, 0°C, 1.5 h; ii) 2N HCl, THF, r.t, 1.5 h, 90.3 %; g. R-Ph-ZnCl (R = H, CH₃, OCH₂Ph), Pd(PPh₃)₄, THF, reflux, 2.5 h, 91 - 94 %; h. I₂, PPh₃, Imidazole, CH₂Cl₂, r.t, 40 min, 93 - 95 %; i. (CH₃)₂NH or pyrrolidine, K₂CO₃, THF, r.t, 20 h, 88.3 - 94.1%; j. ClSO₂NH₂, 2,6-di-tert-butyl-4-methylpyridine, r.t, 1 h, 91 - 94 %; k. H₂, 10% Pd/C, CH₂Cl₂-CH₃OH (3:1), r.t, 1 h, 79.2 % for 4, 82 % for 8.

The synthesis of compounds 1 - 8 is summarized in scheme 1. Reaction of 4-bromophenol 9 with ethyl bromoacetate gave ester 10 (99.3 %). Reduction of 10 with LiAlH₄ followed by protection of the resulting alcohol 11 as TBS ether yielded compound 12 (96.4 % for 2 steps). Treatment of 12 with n-butyl lithium, then with ketone 13 which was prepared by tetrahydropyranylayion of 6-hydroxy-1-tetralone (98%), followed by dehydration of the resulting tertiary alcohol with silica gel, afforded olefin 14 (65.7% based on 13). Bromination of compound 14 with pyridinium tribromide followed by acidic hydrolysis furnished the vinyl bromide 15 (90.3%). Palladium catalyzed coupling³¹ of compound 15 with various para-substituted phenyl zinc chlorides which were prepared by the treatment of the corresponding substituted phenylbromides with n-butyl lithium followed by zinc chloride, gave compounds 16 - 19 (91-94%). Iodination of alcohols 16 - 19 with I₂/PPh₃/Imidazole yielded the iodides 20 - 23 (93-95%). Reaction of compounds 20 - 23 with dimethylamine or pyrrolidine gave the corresponding amines 24 - 27 and 28 - 31 respectively (88.3 -94.1%). Sulfamoylation³² of 24 -26 and 28 - 30 with sulfamoyl chloride in the presence of hinder base: 2,6-di-tert-butyl-4-methyl pyridine, yielded the target compounds 1 - 3 and 5 - 7 respectively. Compound 4 was synthesized by sulfamoylation of compound 27 to form compound 32 followed by debenzylation through hydrogenation. The synthesis of inhibitor 8 was similar to 4 except compound 31 was sulfamoylated instead.



References and Notes

- 1. Noel, C.T.; Reed, M.J.; Jacobs, H.S.; James, V.H.T. J. Steroid Biochem. 1981, 14, 1101.
- 2. Samojlik, E.; Santen, R.J.; Worgul, T.J. Steroids 1982, 39, 497.
- 3. Santner, S.J.; Feil, P.D.; Santen, R.J. J. Clin. Endocrinol. Metab. 1984, 59, 29.
- 4. Pasqualini, J.R.; Chetrite, G.; Nguyen, B.L.; Maloche, C.; Delalonde, L.; Talbi, M.; Feinstein, M.C.; Blacker, C.; Botella. J.; Paris, J. J. Steroid Biochem. & Molec. Biol. 1995, 59, 407.
- 5. Duncan, L.; Puroit, A.; Howarth, N.M.; Potter, B.V.L.; Reed, M.J. Cancer Res. 1993, 53, 298.
- 6. Howarth, N.M.; Cooper, G.; Purohit, A.; Duncan, L.; Reed, M.J.; Potter, B.V.L. *Bioorg. Med. Chem. Lett.* 1993, 3, 313.
- 7. Li, P.K.; Pillai, R.; Young, B.L.; Bender, W.H.; Martino, D.M.; Lin, F.T. Steroids 1993, 58, 106.
- 8. Howarth, N.M.; Purohit, A.; Reed, M.J.; Potter, B.V.L. J. Med. Chem. 1994, 37, 219.
- 9.Dibbelt, L.; Li, P.K.; Pillai, R.; Knuppen, R. J. Steroid Biochem. Molec. Biol. 1994, 50, 261.
- 10. Dibbelt, L.; Li, P.K.; Pillai, R.; Knuppen, R. J Steroid Biochem. & Molec. Biol. 1995, 52, 281.
- 11. Purohit, A.: Williams, G.J.: Howarth, N.M.: Potter, B.V.L.; Reed, M.J. Biochemistry 1995, 34, 11508.
- 12. Purohit, A.; Williams, G.J.; Roberts, C.J.; Potter, B.V.L.; Reed, M.J. Int. J. Cancer 1995, 63, 106.
- 13. Li, P.K.; Pillai, R.; Dibbelt, L. Steroids 1995, 60, 299.
- 14. Li, P.K.; Milano, S.; Kluth, L.; Rhodes, M.E. J. Steroid Biochem. & Molec. Biol. 1996, 59, 41.
- 15. Selcer, K.W.; Jagannathan, S.; Rhodes, M.E.; Li, P.K. J. Steroid Biochem. & Molec. Biol. 1996, 59, 83.
- 16. Woo, L.W.; Lightowler, M.; Purohit, A.; Reed, M.J.; Potter, B.V.L. *J Steroid Biochem. & Mol. Biol.* **1996**, *57*, 79.
- 17. Woo, L.W.; Purohit, A.; Reed, M.J.; Potter, B.V.L. J Med. Chem. 1996, 39, 1349.
- 18. Selcer, K.W.; Hedge P.; Li, P.K. Cancer Res. 1997, 57, 702.
- 19. Chu, G.H.; Milano, S.; L. Kluth, Rhodes, M.E.; Johnson, D.A.; Li, P.K. Steroids 1997, 62, 530.
- 20. Li, P.K.; Chu, G.H.; Peters, A.; Selcer, K.W. Steroids 1998, 63, 425.
- 21. Poirier, D.; Boivin, R.P. Bioorg. Med. Chem. Lett. 1998, 8, 1891.
- 22. Purohit, A.; Vernon, K.A.; Hummelinck, A.E.; Woo, L.W.; Hejaz, H.A.; Potter, B.V.; Reed, M.J. *J Steroid Biochem. Mol. Biol.* 1998, 64, 269.
- 23. Woo, L.W.; Howarth, N.M.; Purohit, A.; Hejaz, H.A.; Reed, M.J.; Potter, B.V.L. *J Med. Chem.* **1998**, 41, 1068.
- 24. Kolli, A.; Chu, G.H.; Rhodes, M.E.; Inoue, K.; Selcer, K.W.; Li, P.K. *J Steroid Biochem. Mol. Biol.* **1999**, *68*, 31.
- 25. Ciobanu, L.C.; Boivin, R.P.; Luu-The, V.; Labrie, F.; Poirier, D. J Med. Chem. 1999, 42, 2280.
- 26. Hejaz, H.A.; Purohit, A.; Mahon, M.F.; Reed, M.J.; Potter, B.V. J Med. Chem. 1999, 42, 3188.
- 27. Chu, G.H.; Peters, A.; Selcer, K.W.; Li, P.K. Bioorg. Med. Chem. Lett. 1999, 9, 141.
- 28. Katzenellenbogen, J.A.; Carlson, K.E.; Katzenellenbogen, B.S. J. Steroid Biochem., 1985, 22, 589.
- 29. Harper, M.J.; Walpole, A.L. Nature 1966, 212, 87.
- 30. Jordon, V.C.; Haldemann, B.; Allen, K.E. Endocrinology 1981, 108, 1353.
- 31. McCague, R.; Leclercq, G.; Jordan, V.C.; J med. Chem. 1988, 31, 1285.
- 32. Schwartz, S.; Thieme, I.; Richter, M.; Undeutsch, B.; Henkel, H.; Elger, W. Steroids, 1996, 61, 710.